Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

683 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

NCT01127620

Perennial Allergic Rhinitis

COMPLETED PHASE3

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

NCT01108783

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

NCT00421109

Urticaria

COMPLETED PHASE3

PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)

NCT00574210

Seasonal Allergic Rhinitis Hay Fever Rhinoconjunctivitis

COMPLETED PHASE2

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379

Seasonal Allergic Rhinitis Hay Fever Allergic Conjunctivitis +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this pivotal, multicentre, international, randomized, double-blind, placebo and active-comparator controlled, parallel study, 683 patients with SAR will be enrolled. Patients will be required to be 12-70 years old, have SAR for ≥2 years, a positive skin test, total nasal and non-nasal score (TSS) ≥36 (out of 72) during run-in, and a composite instantaneous nasal symptom score ≥6 (out of 12) the morning before randomization. The primary efficacy endpoint will be the AUC of reflective TSS from baseline to Day 14.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seasonal Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Bilastine

Group Type EXPERIMENTAL

bilastine

Intervention Type DRUG

20 mg (encapsulated) tablets QD/14days

B

Cetirizine

Group Type ACTIVE_COMPARATOR

Cetirizine

Intervention Type DRUG

10 mg (encapsulated) tablets. QD/14 days

C

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

(encapsulated) Tablets QD/14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bilastine

20 mg (encapsulated) tablets QD/14days

Intervention Type DRUG

Cetirizine

10 mg (encapsulated) tablets. QD/14 days

Intervention Type DRUG

Placebo

(encapsulated) Tablets QD/14 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zyrtec

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of either sex between 12 and 70 years of age.
* Patients with documented clinical history of SAR, for at least 2 years prior to the study inclusion.
* Positive skin prick test for at least one of the seasonal allergen specific of the geographical area.
* A previous positive Prick test, or a positive IgE Test (RAST) may also be accepted for inclusion, if performed within 12 months prior to the inclusion.

Exclusion Criteria

* Patients who have non-allergic rhinitis (vasomotor, infectious, drug-induced, etc.).
* Negative skin prick test (as defined in point 6.1.1.).
* Patients with nasal polyps or a significant deviation of the nasal septum as judged by the investigator as well as nasal intervention in the previous 6 months. Any other nasal illness that can interfere with the aim of the study.
* Patients who have acute or chronic sinusitis as judged by the investigator.
* Patients who have received anti-allergy immunotherapy in the previous two years or are still receiving this kind of therapy.
* Patients who are taking or have taken specified medications prior to randomisation in the study and have not complied with the specified washout period

Minimum Eligible Age

12 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No